CD276/B7-H3 Inhibitor

Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators.

Ifinatamab is monoclonal immunoglobulin G1-kappa with anti-human B7 homolog 3 protein (Human B7-H3). Ifinatamab is a glycoforme α immunomodulateur.

Omburtamab (Mab 8H9) is a mouse monoclonal immunoglobulin G1 (IgG1) antibody targeting B7-H3. Omburtamab specifically binds to the glycoprotein antigen B7-H3, which is widely expressed on the surface of tumor cells. As a targeting carrier for recombinant toxins, it delivers PE38 to inhibit cellular protein synthesis and induce cytotoxicity in antigen-expressing cancer cells. Omburtamab can be used in research related to glioma, breast cancer, osteosarcoma and neuroblastoma.

Puxitatug samrotecan (AZD 8205) is an antibody-drug conjugate (ADC) targeting B7-H4, formed by the random conjugation of the Puxitatug (HY-P990059) antibody and AZ14170133 (HY-145399) via interchain cysteine reduction. Puxitatug samrotecan binds to B7-H4 to deliver the payload to B7-H4-expressing cells, inhibits topoisomerase I, and induces cytotoxicity in cancer cells and xenograft models. Puxitatug samrotecan can be used in studies of B7-H4-expressing tumors.

Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer.

Piperacetazine is an orally active dopamine receptor antagonist and phenothiazine antipsychotic. Piperacetazine can directly bind to the PAX3::FOXO1 fusion protein and inhibit its transcriptional activity. Piperacetazine also exhibits antitumor activity with an IC₅₀ of 7.627 μM against PANC-1 cells. Piperacetazine can be used for the research of diseases such as schizophrenia and pancreatic cancer and other tumors.

HS-20093 Antibody (GSK5764227 Antibody) is an antibody targeting B7-H3, which can be used to synthesize the ADC HS-20093. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors.

Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC).

Mocertatug (GSK5733584 antibody) is a humanized IgG1κ antibody targeting B7-H4/VTCN1. Mocertatug can be used to construct ADCs, such as Mocertatug Rezetecan (HY-185280).

Elfetabart (DB-1311 Antibody; BNT324 Antibody) is a humanized monoclonal antibody targeting CD276 with antitumor activity. The antibody isotype of Elfetabart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

IBI-334 is a bispecific B7-H3 and EGFR antibody. IBI-334 has an EGFR arm for signal blockage and is coupled with a fine-tuned B7-H3 arm with optimal affinity and binding domain. IBI-334 shows antibody-mediated cell cytotoxicity (ADCC) effects. IBI-334 has a wide range of applications in many EGFR-driven solid tumors.

IBI-334 (FUT8-KO) is a bispecific B7-H3 and EGFR antibody that has knocked out the fucosyltransferase 8 gene (FUT8). IBI-334 (FUT8-KO) has an EGFR arm for signal blocking and is coupled with a fine-tuned B7-H3 arm with the best affinity and binding domain. IBI-334 (FUT8-KO), compared to IBI-334 (HY-P991092), has enhanced antibody-mediated cytotoxicity (ADCC) effect. IBI-334 (FUT8-KO) has wide applications in many EGFR-driven solid tumors.

HBM1020 is a fully human monoclonal antibody targeting B7H7. HBM1020 binds to B7H7 and enhances the anti-tumor response of T cells. HBM1020 can be used in research related to advanced solid tumors.

Anti-B7-H3/CD276 Antibody is a CHO-expressed human antibody targeting B7-H3/CD276. Anti-B7-H3/CD276 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H3/CD276 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

DS-5573a is a human monoclonal antibody targeting B7-H3, with a K_d of 1.8 nM for the 4Ig isoform and 11 nM for the 2Ig isoform. DS-5573a induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against B7-H3-expressing cancer cells. DS-5573a exerts dose-dependent anti-tumor activity via effector cells. DS-5573a can be used in the research of cancers including breast adenocarcinoma, non-small cell lung cancer, renal cell adenocarcinoma, gastric cancer and prostate cancer.